Abstract: Cell and gene therapy supply chains are uniquely complex, requiring precise coordination, regulatory compliance, and robust logistics to ensure timely delivery of life-saving treatments.

Abstract: Choosing between modular and fully integrated manufacturing platforms is a critical decision for cell therapy developers, impacting scalability, cost efficiency, and commercial viability.

Abstract: Process characterization is essential for cell therapy programs, ensuring consistent, safe, and effective products that meet regulatory standards.

Abstract: Cell therapies have complex manufacturing needs since the final drug product is viable cells comprising thousands of proteins, lipids and carbohydrates that can change with every manipulation step.

Abstract: Open steps in cell therapy manufacturing expose products to contamination risk, operational complexity, and scalability limitations.

Abstract: Cell therapy manufacturing demands rigorous quality control, as living cell products cannot be terminally sterilized and are often produced in small batches.

Abstract: Cell therapy manufacturing is advancing rapidly, offering new therapeutic options for challenging diseases, but the complexity of production makes raw material selection a critical determinant of success.

Abstract: Transient transfection-based AAV manufacturing continues to face an industry-wide yield ceiling, limiting scalability, increasing costs, and challenging the commercial viability of gene therapy programs.

Abstract: Late‑phase program transfers often arrive with years of thoughtful process characterization (PC), carefully defined control strategies, and a deep scientific rationale that sponsors are rightly committed to preserving.

Abstract: For decades, biologics stability programs followed a predictable playbook: generate data, support regulatory filings, satisfy agencies, and move on.